Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of liposomal irinotecan + S-1 + camrelizumab in previously treated advanced metastatic esophageal squamous cell carcinoma
ChiCTR2500102389Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan, tegafur and camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecantegafurcamrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500102389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102389.